AVERTIS

AI-Powered Breast Screening:
Faster, Smarter, Better

AVERTIS

Why do we need **_ARTIFICIAL INTELLIGENCE_** to **_REVOLUTIONIZE_** the screening process?

***Breast cancer** is the **most prevalent cancer** diagnosed among females **worldwide**

2.3 MILLION
New breast cases

685,000
Breast cancer deaths

AVERTIS

[1] Giaquinto, A.N., Sung, H., Miller, K.D., Kramer, J.L., Newman, L.A., Minihan, A., Jemal, A. and Siegel, R.L. (2022), Breast Cancer Statistics, 2022. CA A Cancer J Clin, 72: 524-541. https://doi.org/10.3322/caac.21754.
[2] S. Lei, R. Zheng, S. Zhang, S. Wang, R. Chen, et al., Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020, Cancer Commun. (Lond.) 41 (11) (2021) 1183–1194, http: //dx.doi.org/10.1002/cac2.12207.

Screening procedures *are implemented to diagnose the disease in its early stages*

Women 50-69 years old: mammography every 2 years

AVERTIS

[3] https://www.salute.gov.it/portale/tumori/dettaglioContenutiTumori.jsp?lingua=italiano&id=5542&area=tumori&menu=screening#:~:text=I%20dati%20del%20Report%20I,%2C5%25%25%20rispetto%20al%202020.
[4] S. Lei, R. Zheng, S. Zhang, S. Wang, R. Chen, et al., Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020, Cancer Commun. (Lond.) 41 (11) (2021) 1183–1194, http://dx.doi.org/10.1002/cac2.12207.

↑ Increasing number of eligible women

↓ Decreasing number of clinicians

Diagnostic tests can take up to 2 years

AVERTIS

Traditional screening limitations

Error-prone procedures

Variability among operators

Lack of personalization

AVERTIS

AVERTIS Innovative Solution

**59% of Italian
medical specialists**

believe AI tools can help them facilitate and improve their professional activities

**5-10% of
healthcare spending**

could be saved through widespread AI adoption in the next five years

AVERTIS

[6] Risultati della ricerca 2022-2023. Osservatorio Artificial Intelligence. Osservatori Digital Innovation, Politecnico di Milano.
[7] https://www.sanita-digitale.com/in-evidenza/l86-dei-medici-italiani-e-favorevole-alluso-della-tecnologia/

AVERTIS Business Model

REVENUE STREAMS

Sale of AI-powered breast screening platform

Monetize our anonymized image database

CUSTOMERS

Public and private hospitals

Research institutes

DEPLOYMENT OPTIONS

On-premises

Cloud-based

**SCALE UP POTENTIAL**

Applicability across diverse body screenings

International market expansion

AVERTIS

Competitive Scenario

AVERTIS competitive advantage

Support to the physicians **throughout** the screening process

Comprehensive **patient data** analysis for **personalized** assessment

Seamless integration with existing healthcare system data infrastructure

Database for empowered breast cancer research

AVERTIS

AVERTIS Team

Valentina Lidoni
CEO

MSc Student Biomedical Eng.
Healthcare & Innovation Analyst

Pablo Giaccaglia
CTO

MSc Student Computer Science Eng.

Leonardo Breda
COO

MSc Student Mathematical Eng.

International experience

Affiliations

POLITECNICO
MILANO 1863

NECST laboratory

Marco D. Santambrogio
Scientific Advisor

Associate Professor

Eleonora D'Arnese
Scientific Advisor

Postdoctoral Researcher

ARTS ET MÉTIERS ParisTech

ESPCI ParisTech

ETH zürich

Université Paris Cité

UIC

INDIAN INSTITUTE OF TECHNOLOGY MADRAS

Project Roadmap

Refinement and optimization → Relevant environment testing → Clinical Trials & Certifications → Market entry & Commercialization

TRL 4 **TRL 5** **TRL 6-7** **TRL 8-9**

Finalize patent application

Sept. '23

MVP

POC

2024   2025   2026   2027   2028

€ 30 - 50 K   € 150 – 250 K   € 1.5 – 2 M

AVERTIS

*Join us in revolutionizing breast cancer screening!*

AVERTIS

Contacts:
avertis.info@gmail.com